Key Highlights

  • Allot, CapsoVision and CS Disco each show a 50-day Moving Average above the 200-day average.
  • Allot raised 2026 Revenue guidance to $115 million to $118 million after a fourth consecutive double-digit growth quarter.
  • CapsoVision received FDA clearance for AI Highlights on September 25 and reported second-quarter revenue growth of 10%.
  • CS Disco grew second-quarter revenue 13% to $43.1 million and guided 2026 revenue to between $172 million and $179 million.
  • Allot holds $107 million of cash and investments, CS Disco $101.4 million, and CapsoVision $9.1 million.

A golden cross occurs when a stock's 50-day simple moving average moves above its 200-day, a pattern technical analysts read as a sign of an improving medium-term trend. It is derived from past prices and says nothing on its own about Earnings quality or funding.

Three smaller companies, each with a market Capitalization below $500 million, have now formed one. They operate in network security, medical devices and legal software, so their fundamentals differ widely. Each is tested below against its latest reported results, guidance and cash position, using company releases and management commentary from the second-quarter reports.

Is Allot's Golden Cross Backed by Recurring Security Revenue?

Allot (NASDAQ:ALLT) is trading up 0.78% at $9.06, with a market capitalization of $446.69 million. The Israel-based company provides network intelligence and security solutions to communications service providers and enterprises, and its security-as-a-service offering, SECaaS, is its fastest-growing line. Allot reported second-quarter results on August 12.

Second-quarter revenue was $27.7 million, up 15%, the fourth consecutive quarter of double-digit growth. SECaaS revenue rose 47% to $9.4 million, or 34% of the total, and SECaaS annual Recurring Revenue reached $36.1 million, up 44%. The chief executive pointed to revenue strength in North America.

GAAP Net Income was $2.6 million, against a net loss of $1.7 million a year earlier, and Operating Cash Flow was $8.5 million. The company raised 2026 revenue guidance to between $115 million and $118 million, expects SECaaS growth of 40% or more, and has a board-approved buyback of up to $40 million against $107 million of cash, deposits and investments.

Non-GAAP gross Margin was 71.8% and GAAP gross margin was 71.3%. Non-GAAP Operating Income was $2.7 million and non-GAAP net income was $4.6 million, or $0.09 per diluted share, while six-month GAAP net income was $4.5 million.

The Americas contributed $8.5 million, or 31% of revenue. The release carries no ARR or EBITDA guidance, and management said only that it expects continued improvement in profitability.

Does CapsoVision's Golden Cross Reflect the FDA Clearance or the Cash Position?

CapsoVision (NASDAQ:CV) is trading up 1.72% at $6.80, with a market capitalization of $361.56 million. The company develops capsule endoscopy systems for gastrointestinal imaging, including CapsoCam Plus. The FDA cleared its AI Highlights reading tool for CapsoCam Plus on September 25, and the product had already launched in the European Union and other international markets.

Second-quarter revenue was $3.6 million, up 10%, with capsule units sold up about 13% and average selling price down about 3%. Gross margin was 51% against 55% a year earlier, which management attributed to competitive pricing and higher customs and Tariff costs. The net loss widened to $7.5 million from $4.6 million.

Cash was $9.1 million at June 30, against $14.5 million of operating cash used in the first half. The company has noted a $14.0 million private Placement in 2026 and an at-the-market Equity program of up to $100 million, and it has not issued full-year guidance. A 510(k) submission for CapsoCam Colon is planned for the fourth quarter.

Operating expenses were $9.5 million, up $3.0 million, reflecting the colon pivotal study and other clinical trials, development engineering work, public-company costs and stock-based compensation. The six-month net loss was $14.5 million.

AI Highlights is cleared for small bowel capsule endoscopy for suspected small bowel bleeding, in adults and in pediatric patients older than two, and is not intended to replace a gastroenterologist's interpretation. Enrollment continues in the CapsoCam UGI study for pancreatic cancer detection.

What Backs CS Disco's Golden Cross After 13% Revenue Growth?

CS Disco (NYSE:LAW) is trading up 1.93% at $4.76, with a market capitalization of $309.02 million. Operating under the DISCO brand, it sells cloud-native, AI-powered software for legal discovery, document review and case management. It reported second-quarter results on August 5.

Second-quarter revenue was $43.1 million, up 13%, with software revenue of $36.8 million, also up 13%. Non-GAAP gross margin was 76%, the GAAP net loss narrowed to $8.7 million from $10.8 million, and adjusted EBITDA was a loss of $3.4 million. The company had 354 customers generating more than $100,000 in trailing twelve-month revenue, up 10%.

Guidance for 2026 calls for total revenue of $172.0 million to $179.0 million and an adjusted EBITDA loss of $5.0 million to $8.0 million. Cash and short-term investments totaled $101.4 million with no borrowings, and net cash used in Operating Activities was $12.8 million in the first half.

Third-quarter guidance is for total revenue of $43.75 million to $45.75 million and an adjusted EBITDA loss of $0.25 million to $1.75 million, with 2026 software revenue guided to $147.5 million to $152.5 million. The GAAP net loss was $0.13 per share against $0.18 a year earlier, and non-GAAP sales and Marketing and Research and Development expenses were $15.7 million and $13.4 million. The release did not disclose annual recurring revenue, and the shares trade below $5.

Signal Versus Balance Sheet

The three signals sit on different financial footing. Allot is profitable on a GAAP basis, generates operating cash and has authorized a buyback. CS Disco is guiding to an adjusted EBITDA loss but holds more than $100 million in cash and investments with no borrowings.

CapsoVision held $9.1 million of cash against $14.5 million of operating cash used in the first half and has an equity program in place. For the quarter, Allot reported GAAP net income of $2.6 million, CS Disco a GAAP net loss of $8.7 million and CapsoVision a net loss of $7.5 million. This comparison is limited to reported results and company guidance and does not assess valuation.